Anticoagulant News and Research

RSS

The American Heart Association and Heart Rhythm Society Unite to Improve Cardiovascular Research, Care

The American Heart Association and Heart Rhythm Society today announced a collaboration designed to advance research and improve the delivery of care for people with an irregular heartbeat known as atrial fibrillation (AFib).

20 Oct 2015

Pacemakers can detect AF and enable initiation of anticoagulation for stroke prevention

Pacemakers can detect asymptomatic AF but are not routinely monitored for this purpose. The current study investigated whether pacemaker checks could be used to identify patients with asymptomatic AF who could then be given anticoagulation for stroke prevention.

19 Oct 2015

FDA grants accelerated approval to Praxbind (idarucizumab)

The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa's blood-thinning effects.

19 Oct 2015

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration granted approval of Praxbind (idarucizumab). PRAXBIND is indicated for patients treated with Pradaxa (dabigatran etexilate mesylate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.

16 Oct 2015

Anti-coagulant medications quickly resolve blood clots that could impair valve motion

Heart valve replacements made from tissue (bioprosthetic valves) have long been thought to be spared the complication of blood clot formation. Researchers have now found that about 15 percent of all bioprosthetic aortic heart valve patients develop blood clots on the leaflets affecting valve opening, regardless of whether the patient received the new valve via open-heart surgery or a minimally-invasive catheter procedure, a new study from the Cedars-Sinai Heart Institute shows.

6 Oct 2015

Acute Cardiovascular Care 2015 to be held in Vienna from 17 to 19 October

Acute Cardiovascular Care 2015 will highlight innovations and controversies in the field, guaranteeing great stories on topics relevant to the press.

18 Sep 2015

Boca Raton Regional Hospital introduces ultra-minimally invasive procedure for patients with atrial fibrillation

Boca Raton Regional Hospital's Richard G. Cartledge, MD, FACS, has begun performing ultra-minimally invasive left atrial appendage ligation for atrial fibrillation patients who are on anticoagulants such as Coumadin, Xarelto or Effient. Dr. Cartledge, who is Chief of Cardiothoracic Surgery at the Hospital, is one of a select group of surgeons nationally using this method, which involves making two microscopic incisions in order to seal off the left atrial appendage (LAA) in patients where anticoagulants are contraindicated or who refuse to be on such medications.

3 Sep 2015

AF patients treated with rivaroxaban for stroke prevention experience low rates of bleeding and stroke

Atrial fibrillation (AF) patients treated with rivaroxaban for stroke prevention have low rates of bleeding and stroke, reveals real-world data from the XANTUS study presented at ESC Congress today.

2 Sep 2015

SLU scientist receives grant to solve blood-clotting mysteries

Last summer, SLU scientists made a breakthrough discovery about the way in which blood clots. Through X-ray crystallography, they solved the molecular structure of prothrombin, an important blood-clotting protein, revealing an unexpected, flexible role for a "linker" region that may be the key to developing better life-saving drugs.

1 Sep 2015

GARFIELD-AF Registry: All-cause death is most frequent major event in newly diagnosed AF patients

The first-ever two-year outcomes from the Global Anticoagulant Registry in the Field - Atrial Fibrillation (GARFIELD-AF) showcased at ESC Congress 2015 expose that all-cause death was the most frequent major event in more than 17,000 newly diagnosed AF patients, far exceeding the rate of stroke or major bleeding.

1 Sep 2015

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF).

1 Sep 2015

Extending bivalirudin treatment after PCI does not improve ischemic and bleeding outcomes

Extending treatment with the anticoagulant bivalirudin for at least four hours after completion of percutaneous coronary intervention (PCI) does not improve outcomes compared to stopping the treatment immediately after the procedure, according to results from the MATRIX Treatment Duration trial.

1 Sep 2015

Educational program does not influence patients’ adherence to apixaban anticoagulant

Adherence to the oral anticoagulant apixaban among patients with atrial fibrillation (AF) was no better for those who received an educational program compared to those who did not, results of the international, randomised AEGEAN trial show.

31 Aug 2015

ESC guideline adherent antithrombotic management improves outcomes in AF patients

Patients with atrial fibrillation who receive antithrombotic management according to ESC guidelines have better outcomes than those who do not, according to one year follow up results from the ESC's EORP-AF Pilot General Registry presented today at ESC Congress 20151 and published online in Europace.

31 Aug 2015

GARFIELD-AF data to demonstrate impact of antithrombotic treatment patterns on AF patients at ESC Congress 2015

New analyses from the Global Anticoagulant Registry in the Field - Atrial Fibrillation (GARFIELD-AF) will be presented at ESC Congress 2015 to be held in London, United Kingdom, from August 29 to September 2, 2015.

20 Aug 2015

Instrumentation Laboratory announces European release of HemosIL Rivaroxaban Testing Solution

Instrumentation Laboratory today announced the commercialization of their HemosIL Rivaroxaban Testing Solution in Europe. The HemosIL Liquid Anti-Xa assay, when used in conjunction with HemosIL Rivaroxaban Calibrators and HemosIL Rivaroxaban controls offers an automated solution for measurement of rivaroxaban.

10 Aug 2015

Cryptogenic stroke frequent and recurrent

Cryptogenic ischaemic strokes and transient ischaemic attacks frequently recur, despite having no identifiable cause, show findings from the Oxford Vascular Study.

4 Aug 2015

Scientists develop artificial blood vessels that are resistant to blood clot formation

Scientists from ITMO University developed artificial blood vessels that are not susceptible to blood clot formation. The achievement was made possible by a new generation of drug-containing coating applied to the inner surface of the vessel.

4 Aug 2015

More people turn to popular new blood thinners for atrial fibrillation treatment

More adults than ever are visiting their doctors' offices for a prescription to treat atrial fibrillation, according to a study led by the University of Michigan Frankel Cardiovascular Center.

23 Jul 2015

Use of dicloxacillin linked to INR decrease in patients taking vitamin K antagonists

Researchers have found an association between treatment with the antibiotic dicloxacillin and a decrease in international normalized ratio (INR; a measure of blood coagulation) levels among patients taking the vitamin K antagonists warfarin or phenprocoumon, according to a study in the July 21 issue of JAMA.

22 Jul 2015

Anticoagulant News and Research

The American Heart Association and Heart Rhythm Society Unite to Improve Cardiovascular Research, Care

Pacemakers can detect AF and enable initiation of anticoagulation for stroke prevention

FDA grants accelerated approval to Praxbind (idarucizumab)

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Anti-coagulant medications quickly resolve blood clots that could impair valve motion

Acute Cardiovascular Care 2015 to be held in Vienna from 17 to 19 October

Boca Raton Regional Hospital introduces ultra-minimally invasive procedure for patients with atrial fibrillation

AF patients treated with rivaroxaban for stroke prevention experience low rates of bleeding and stroke

SLU scientist receives grant to solve blood-clotting mysteries

GARFIELD-AF Registry: All-cause death is most frequent major event in newly diagnosed AF patients

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Extending bivalirudin treatment after PCI does not improve ischemic and bleeding outcomes

Educational program does not influence patients’ adherence to apixaban anticoagulant

ESC guideline adherent antithrombotic management improves outcomes in AF patients

GARFIELD-AF data to demonstrate impact of antithrombotic treatment patterns on AF patients at ESC Congress 2015

Instrumentation Laboratory announces European release of HemosIL Rivaroxaban Testing Solution

Cryptogenic stroke frequent and recurrent

Scientists develop artificial blood vessels that are resistant to blood clot formation

More people turn to popular new blood thinners for atrial fibrillation treatment

Use of dicloxacillin linked to INR decrease in patients taking vitamin K antagonists

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News